1[2]Bellmann R,Egger P,Gritsch W,et al.Elimination of levofloxacinin critically ill patients with renal failure:influence of continuous veno-venous hemofiltration[J].Int J Clin Pharmacol Ther,2002,4:142.
2[5]Croom KF,Goa KL.Levofloxacin:a review of its use in the treatment of bacterial infections in the United States[J].Drugs,2003,24:2769.
3[9]Stahlmann R,Lode H.Fluoroquinolones in the elderly:safety considerations[J].Drugs Aging,2003,4:289.
4国家药典委员会.中华人民共和国药典临床用药须知[M].北京:化学工业出版社,2001..
5BALL P. Quinolone generations: natural history or natural selection? [ J] JAntimicrob Chemother, 2000, 46 (Suppl T1 ) : 17-24.
6ANDERSSON M I, MACGOWAN A P. Development of the quinolones[ J].J Antimicrob Chemother, 2003, 51 (Suppl 1) : 1-11.
7AKTAS Z, GONULLU N, SALCIOGLU M, et al. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin[J]. Int J Antimicrob Agents, 2002, 20 (3) : 196-200.
8ROLSTON KV, FRISBEE-HUME S, LEBLANC B, et al. In vitro antimi-crobial activity of moxifloxacin compared to other quinolones against recenl clinical bacterial isolates from hospitalized and community-based cancer patients[J]. Diagn Microbiol Infect Dis, 2003, 47 (2): 441-449.
9HOOPER D C. Mechanisms of action and resistance of older and newer fluoroquinolones [ J ]. Clin Infect Dis, 2000, 31 ( Suppl 2 ) :S24-S28.
10HOOPER D C, Mechanisms of action of antimierobials: focus on fluoroqui-nolones[J]. Clin Infect Dis, 2001,32 (Suppl 1) : S9-S15.
2Sikdar KC, Dowden J, Alaghehbandan R, et al. Adverse drug reactions in elderly hospitalized patients:a 12-year population-based retrospective co- holt study[J]. Ann Pharmacother,2012,46(7 -8) :960 -971.
3Martin RM, Biswas PN, Freemantle SN, et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England:analysis of 48 cohort studies [ J ]. Br J Clin Pharma- co1,1998,46(5) :505 -511.
